-
Product Insights
Hypersecretory Conditions – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypersecretory Conditions - Drugs In Development, 2023’, provides an overview of the Hypersecretory Conditions pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypersecretory Conditions, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Systemic Mastocytosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Mastocytosis - Drugs In Development, 2023’, provides an overview of the Systemic Mastocytosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mast Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Mast Cell Leukemia - Drugs In Development, 2023’, provides an overview of the Mast Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mast Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Solid Tumor Drug Details: Avapritinib (Ayvakit, Ayvakyt) is an anti-neoplastic agent. It is...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor Of The Gastrointestinal Tract - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor Of The Gastrointestinal Tract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Chronic Urticaria Or Hives – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Urticaria Or Hives - Drugs In Development, 2023’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mesenchymal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Singapore Telecom Operators Country Intelligence Report
Singapore Telecom Services Market Overview The total telecom and pay-TV service revenue in Singapore, when valued in local currency, is expected to increase at a CAGR of 0.3% during 2023-2028, primarily supported by fixed broadband and mobile data segments. However, when valued in the US dollars, the revenue seems to decline at a CAGR of 0.2% during the same period, due to the strengthening of the US dollar against the local currency. Singapore Telecom Services Market Outlook, 2023 – 2028...